Meeder Asset Management Inc. boosted its holdings in Celgene Co. (NASDAQ:CELG) by 135.2% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 14,089 shares of the biopharmaceutical company’s stock after acquiring an additional 8,098 shares during the quarter. Meeder Asset Management Inc.’s holdings in Celgene were worth $2,054,000 as of its most recent filing with the SEC.
Other institutional investors have also recently bought and sold shares of the company. First National Bank of Hutchinson raised its holdings in shares of Celgene by 57.6% in the 3rd quarter. First National Bank of Hutchinson now owns 5,136 shares of the biopharmaceutical company’s stock worth $750,000 after purchasing an additional 1,878 shares during the period. Fisher Asset Management LLC raised its holdings in shares of Celgene by 0.7% during the 3rd quarter. Fisher Asset Management LLC now owns 265,695 shares of the biopharmaceutical company’s stock valued at $38,744,000 after buying an additional 1,766 shares during the period. Wendell David Associates Inc. raised its holdings in shares of Celgene by 4.2% during the 3rd quarter. Wendell David Associates Inc. now owns 92,735 shares of the biopharmaceutical company’s stock valued at $13,523,000 after buying an additional 3,735 shares during the period. Arcadia Investment Management Corp MI raised its holdings in shares of Celgene by 118.7% during the 3rd quarter. Arcadia Investment Management Corp MI now owns 737 shares of the biopharmaceutical company’s stock valued at $107,000 after buying an additional 400 shares during the period. Finally, Assenagon Asset Management S.A. acquired a new stake in Celgene during the 3rd quarter valued at approximately $14,700,000. 79.74% of the stock is currently owned by institutional investors.
A number of equities research analysts have weighed in on CELG shares. Royal Bank of Canada lowered their price objective on Celgene from $166.00 to $148.00 and set a “top pick” rating for the company in a research note on Friday, October 27th. Leerink Swann reiterated a “buy” rating and issued a $156.00 target price on shares of Celgene in a research report on Friday, October 20th. Morgan Stanley reduced their price objective on Celgene from $120.00 to $115.00 and set an “underweight” rating for the company in a research report on Monday, October 23rd. SunTrust Banks reduced their price objective on Celgene from $156.00 to $127.00 and set a “buy” rating for the company in a research report on Friday, October 27th. Finally, William Blair reaffirmed an “outperform” rating on shares of Celgene in a research report on Friday, October 20th. One investment analyst has rated the stock with a sell rating, fourteen have given a hold rating and nineteen have given a buy rating to the company’s stock. Celgene currently has an average rating of “Buy” and a consensus target price of $131.18.
Celgene Co. (NASDAQ CELG) traded down $0.88 during midday trading on Thursday, hitting $104.58. 7,010,000 shares of the company’s stock were exchanged, compared to its average volume of 6,250,000. The company has a current ratio of 3.65, a quick ratio of 3.52 and a debt-to-equity ratio of 1.31. Celgene Co. has a 12-month low of $94.55 and a 12-month high of $147.17. The company has a market capitalization of $82,340.00, a PE ratio of 24.67, a PEG ratio of 0.68 and a beta of 1.77.
Celgene (NASDAQ:CELG) last issued its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, topping the consensus estimate of $1.87 by $0.04. Celgene had a net margin of 30.06% and a return on equity of 43.32%. The company had revenue of $3.29 billion for the quarter, compared to analysts’ expectations of $3.42 billion. During the same quarter in the previous year, the firm posted $1.58 earnings per share. Celgene’s revenue for the quarter was up 10.2% on a year-over-year basis. analysts expect that Celgene Co. will post 6.68 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: This story was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this story on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2018/01/11/celgene-co-celg-shares-bought-by-meeder-asset-management-inc.html.
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.